Refine
Year of publication
Document Type
- Preprint (685)
- Article (684)
- Working Paper (6)
- Conference Proceeding (3)
- Doctoral Thesis (3)
- Report (2)
Has Fulltext
- yes (1383) (remove)
Is part of the Bibliography
- no (1383)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- COVID-19 (4)
- Cancer (4)
- Collective Flow (4)
- Depression (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Biomarkers (3)
- Epilepsy (3)
- Genetics (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Magnetic resonance imaging (3)
- Seizure (3)
- acute myeloid leukemia (3)
- pp collisions (3)
- Accelerators & Beams (2)
- Acute myeloid leukemia (2)
- Algorithms (2)
- Artificial intelligence (2)
- Atomic, Molecular & Optical (2)
- Beauty production (2)
- Biomarker (2)
- Bipolar disorder (2)
- Bone density (2)
- CT (2)
- CV9202 (2)
- Charm physics (2)
- Cohort studies (2)
- Costs (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- FGFR (2)
- Frieden (2)
- Friedenskonferenz (2)
- Heavy Quark Production (2)
- Immunology (2)
- Intensive care units (2)
- Lepton-Nucleon Scattering (experiments) (2)
- MRI (2)
- MSC (2)
- MSC2013 (2)
- Mitochondria (2)
- Multidetector computed tomography (2)
- München (2)
- Neoplasms (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Pre-analytics (2)
- Psychiatric disorders (2)
- QCD (2)
- Quality of life (2)
- Quarkonium (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Sicherheitskonferenz (2)
- Single electrons (2)
- Spine (2)
- Surgery (2)
- Tomography (2)
- Tomography (x-ray computed) (2)
- apoptosis (2)
- childhood acute myeloid leukemia (2)
- computed tomography (2)
- growth inhibition (2)
- immunotherapy (2)
- land use (2)
- liver (2)
- lung cancer (2)
- portal hypertension (2)
- relapse (2)
- salvage therapy (2)
- security conference (2)
- storage rings (2)
- 19F (1)
- 3 mm RAS instruments (1)
- 3 mm instruments (1)
- 3years (1)
- 900 GeV (1)
- ABCB1 (1)
- ABCC1 (1)
- ABCG2 (1)
- ACLF (1)
- ADGRE1 (1)
- AKI (1)
- AKT (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- APRI (1)
- Ablation Techniques (1)
- Accelerators & storage rings (1)
- Acquired drug resistance (1)
- Acquired resistance (1)
- Active middle ear implants (1)
- Acuris (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Adolescents (1)
- Age determination by skeleton (1)
- Age groups (1)
- Aktienmarkt (1)
- Alpha-synuclein (1)
- Alternative oxidase (1)
- Alzheimer (1)
- Amino acid analysis (1)
- Amyloid precursor protein (1)
- Anemia (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antifungal agents (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Aortic valve replacement (1)
- Applikationen (1)
- Archaeogeophysics (1)
- Artificial Intelligence (1)
- Aspergillosis (1)
- Atomic & molecular beams (1)
- Auditory system (1)
- Autofreies Wohnen (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Autoreduziertes Wohnen (1)
- Awareness campaign (1)
- B cell receptor (1)
- BI1361849 (1)
- Beam loss (1)
- Behavior (1)
- Behavioral disorders (1)
- Bike-Sharing (1)
- Biodiversity (1)
- Biodiversity Data (1)
- Biogeochemistry (1)
- Biological heart valves (1)
- Biomonitoring (1)
- Bioprosthesis (1)
- Biopsy (1)
- Bleeding (1)
- Blood (1)
- Blood sample handling (1)
- Bloodstream infections (1)
- Bone conduction devices (1)
- Bone diseases, Metabolic (1)
- Bone marrow (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brachiopoda (1)
- Brachiozoa (1)
- Breathing (1)
- Bryozoa (1)
- Business strategy in drug development (1)
- C-reactive protein (1)
- CABG (1)
- CAD/ CAM crown (1)
- CAKUT (1)
- CNDAC (1)
- COMT (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CT-guidance (1)
- CTLA-4 (1)
- Calcium (1)
- Cancer Staging (1)
- Cancer check up (1)
- Cancer staging (1)
- Car-Sharing (1)
- Carbon cycle (1)
- Cardiac surgery (1)
- Carsharing (1)
- Cell membranes (1)
- Central Europe (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charged-particle multiplicity (1)
- Checkpoint inhibitor (1)
- Chemicals of emerging concern (1)
- Chemoembolization (1)
- Chemotherapy (1)
- Child abuse (1)
- Childhood abuse (1)
- Children (1)
- Chondral Lesion (1)
- Circular accelerators (1)
- Cirrhosis (1)
- Cleanliness level (1)
- Climate-change ecology (1)
- Clinical genetics (1)
- Clinical trial (1)
- Clinical variation (1)
- Cochlear implantation (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Collectivity (1)
- Colon capsule endoscopy (1)
- Combined immune checkpoint blockade (1)
- Combo® DTS (1)
- Community ecology (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Complex II (1)
- Complex posttraumatic stress disorder (1)
- Compositional bias (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computed tomography, X-ray (1)
- Computer-aided drug design (1)
- Cone-beam computed tomography (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- Conservation biology (1)
- Contrast agent (1)
- Correlation (1)
- Couch tracking (1)
- Cryoelectron microscopy (1)
- DCK (1)
- DME (1)
- DNA sequence analysis (1)
- DNA taxonomy (1)
- DNA-PAINT (1)
- DSM (1)
- Darmstadt (1)
- Data sharing (1)
- Di-hadron correlations (1)
- Diagnostic imaging (1)
- Diagnostic markers (1)
- Dialectical behavioural therapy (1)
- Diffraction (1)
- Digitization (1)
- Direct oral anticoagulation (1)
- Direct reactions (1)
- Drug screens (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dual-energy computed tomography (1)
- EGFR (1)
- EMR1 (1)
- ETP-ALL (1)
- East–west divide (1)
- Eating disorders (1)
- Ecological modelling (1)
- Ecological networks (1)
- Ecosystem ecology (1)
- Ectoprocta (1)
- Edema (1)
- Elastic scattering (1)
- Elderly (1)
- Electric stimulation (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elektromobilität (1)
- Ellenberg indicator values (1)
- Elliptic flow (1)
- Embryos (1)
- Endocannabinoids (1)
- Environmental impact (1)
- European stock markets (1)
- Europäische Aktienmärkte (1)
- Europäische Union (1)
- Everolimus (1)
- Evidence-based guidelines (1)
- Exudates and transudates (1)
- Eye movements (1)
- F4/80 (1)
- FBS (1)
- FFLU (1)
- FIB-4 (1)
- FLT3 (1)
- Facial nerve (1)
- Fahrradverleihsysteme (1)
- Feasibility studies (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flottenkonzepte (1)
- Forest ecology (1)
- Forschung (1)
- Frailty (1)
- Full waveform (1)
- Functional outcomes (1)
- GPS collar (1)
- GWAS (1)
- Gene expression (1)
- General practitioners (1)
- Gimbaled tracking (1)
- Glioblastoma survival (1)
- Global positioning system (1)
- Gram negative bacteria (1)
- Groomed jet radius (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HBT (1)
- HBV (1)
- HCC (1)
- HIV (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Head and neck cancer (1)
- Health information (1)
- Health policy (1)
- Health-seeking behaviour (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hematologic malignancies (1)
- Hematology (1)
- Hematopoietic stem cell transplantation (1)
- Hepatitis C virus (1)
- Herbaria (1)
- Herniated disk (1)
- Hif-1 alpha (1)
- High-dose chemotherapy (1)
- Hodgkin lymphoma (1)
- Hsp70 (1)
- Hypertension (1)
- Hypochondriasis (1)
- Hypofractionated radiotherapy (1)
- IHC (1)
- ILUVIEN (1)
- INR (1)
- Image processing (1)
- Image processing (computer-assisted) (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- In-TIPS thrombosis (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Inflammation (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- International normalized ratio (1)
- Interpretation (1)
- Intervertebral disc displacement (1)
- Intrinsic resistance (1)
- Invariant Mass Distribution (1)
- Invasive candidiasis (1)
- Inversion (1)
- Ionisation energy loss (1)
- Ipilimumab (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- K3EDTA plasma sampling (1)
- KDIGO (1)
- Kidney (1)
- Knockout (1)
- Kryptrochozoa (1)
- LVSPE (1)
- Ladeinfrastruktur (1)
- Lehre (1)
- Lenalidomide (1)
- Leukemia (1)
- Leukemias (1)
- Library screening (1)
- Lincoln-Siedlung (1)
- Lipidol (1)
- Lipidomics (1)
- Liver (1)
- Liver diseases (1)
- Liver transplantation (1)
- Local control (1)
- Lophophorata (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Low-molecular-weight heparin (1)
- Luciferase (1)
- MALAT1 (1)
- MEDIC (1)
- MLC tracking (1)
- MTOR inhibitor (1)
- MYC (1)
- Mass spectrometry (1)
- Mastoiditis (1)
- Material budget (1)
- Medical Oncology (1)
- Melanoma (1)
- Mental health and psychiatry (1)
- Meriç River (1)
- Metabolomics (1)
- Metastasis (1)
- Micropollutants (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitfahrangebote (1)
- Mitochondrial disease (1)
- Mitoxantrone (1)
- Mixed hearing loss (1)
- Mixture risk assessment (1)
- Mobil-Stationen (1)
- Mobilität (1)
- Mobilitätskonzept (1)
- Mobilitätsstationen (1)
- Mobilitätsverhalten (1)
- Model of evolution (1)
- Molecular diagnostic testing (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidetector Computed Tomography (1)
- Multifaktorenmodelle (1)
- Multimodalität (1)
- Multiple factor models (1)
- Multiple myeloma (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Mutation databases (1)
- Mycoses (1)
- Myocarditis (1)
- NAFLD (1)
- NK cells (1)
- NMR spectroscopy (1)
- NOTCH (1)
- NOTCH1 (1)
- NSF (1)
- NVBP (1)
- Neural network (1)
- Neuronal morphology (1)
- Neuroscience (1)
- Neutropenia (1)
- Nivolumab (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Obsessive-compulsive disorder (1)
- Oldest-old (1)
- Organ motion (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- Oxygen (1)
- PD-1 (1)
- PD-L1 (1)
- PLX4032 (1)
- PLX4720 (1)
- PRoMPT (1)
- PSA screening (1)
- PSA-Screening (1)
- PTEN (1)
- PYTHIA (1)
- Parken (1)
- Parkinson’s disease (1)
- Particle and Resonance Production (1)
- Patellofemoral Joint (1)
- Patterns of care (1)
- Pb–Pb (1)
- Pedelecs (1)
- Personenmobilität (1)
- Phantoms (imaging) (1)
- Phoronida (1)
- Phosphate (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- Phylloscopidae (1)
- Phylloscopus (1)
- Phylogeography (1)
- PillCamColon2 (1)
- Plasma (1)
- Point-of-care testing (1)
- Polarization (1)
- Polyps (1)
- Polysomnography (1)
- Polyzoa (1)
- Positive fluid balance (1)
- Positron emission tomography (1)
- Post-traumatic stress disorder (1)
- Postoperative atrial fibrillation (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Prävention (1)
- Psoriasis vulgaris (1)
- Psychological and psychosocial issues (1)
- Pulmonary embolism (1)
- QGP (1)
- QSARs (1)
- Quantitative Imaging (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- RNA (1)
- RNA, long noncoding (1)
- RNActive (1)
- RSL curve (1)
- Radiation detectors (1)
- Radical prostatectomy (1)
- Radiology (1)
- Radiomics (1)
- Radiotherapy (1)
- Randomised controlled trial (1)
- Rapidity Range (1)
- Rare diseases (1)
- Region Rhein-Main (1)
- Registries (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Respiration (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Retrospective studies (1)
- Retrospective study (1)
- Rhabdomyoma (1)
- Ribosome (1)
- Risk drivers (1)
- River pollution (1)
- Robotic tracking (1)
- SAMHD1 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SLC20A1 (1)
- SMAD (1)
- SPSS (1)
- STIR (1)
- Salivary gland carcinoma (1)
- Sampling protocol (1)
- Sapacitabine (1)
- Second-line treatment (1)
- Seicercus (1)
- Semantics (1)
- Senescence (1)
- Sequence (1)
- Serum (1)
- Shear viscosity (1)
- Shell model (1)
- Single muons (1)
- Sleep (1)
- Sleep deprivation (1)
- Small molecules (1)
- Social anxiety disorder (1)
- Sociodemographic characteristics (1)
- SoftDrop (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Spinal fractures (1)
- Spine density (1)
- Splitting function (1)
- Stenotrophomonas maltophilia (1)
- Steroid (1)
- Subependymal giant cell astrocytoma (1)
- Surface waters (1)
- Surveys (1)
- Survival analysis (1)
- Survival data (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T-ALL (1)
- TGFβ (1)
- TGR(mREN2)27 (1)
- TIPS (1)
- TP53 mutation status (1)
- TR (1)
- TSC (1)
- Target screening (1)
- Targeted therapy (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Telemedicine (1)
- Territorial songs (1)
- Therapeutic anticoagulation (1)
- Time Projection Chamber (1)
- Tracking (1)
- Traditional Chinese Medicine (TCM) (1)
- Transcriptome analysis (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- USP28 (1)
- Umweltbilanz (1)
- University hospitals (1)
- Universitätskliniken (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Ursus arctos (1)
- Uveal melanoma (1)
- VEGFR (1)
- Vaccination (1)
- Valve surgery (1)
- Vasculitis (1)
- Vector Boson Production (1)
- Vemurafenib (1)
- Vesicles (1)
- Vincristine (1)
- Virtual noncalcium reconstructions (1)
- Vorsorgeuntersuchung (1)
- Weiterbildung (1)
- Western diet (1)
- Wohnumzug (1)
- X-ray computed (1)
- X-rays (1)
- Xenon-based gas mixture (1)
- abdominal imaging (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- activity sensors (1)
- acute decompensation (1)
- acute lymphoblastic leukemia (1)
- acute-on-chronic liver failure (1)
- adjuvant chemotherapy (1)
- aegean (1)
- age (1)
- amphiregulin (1)
- amygdalin (1)
- anaplastic large cell lymphoma (1)
- anterior chamber depth changes (1)
- anti-EGFR therapy (1)
- antiepileptic drugs (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- archeological sea-level limiting points (1)
- artesunate (ART) (1)
- artifacts (1)
- artificial intelligence (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- autophagy (1)
- bacterial leakage (1)
- beads (1)
- bioactivity testing (1)
- biogeographic legaciese (1)
- bioindication (1)
- biomarker (1)
- bladder cancer (BCa) (1)
- bladder exstrophy-epispadias complex (1)
- breast cancer (1)
- brown bear (1)
- cabazitaxel (1)
- cabozantinib (1)
- carbapenem resistance (1)
- cardiac arrest (1)
- case study (1)
- castration resistance (1)
- cataract surgery (1)
- cell lines (1)
- cell therapy (1)
- cell-free protein synthesis (1)
- characteristic species (1)
- chemorefractory metastatic colorectal cancer (1)
- children and adolescents (1)
- chronic total occlusion (1)
- cilia (1)
- cirrhosis (1)
- cisplatin resistance (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- colorectal cancer (1)
- complementary/alternative medicine (CAM) (1)
- computer tomography (1)
- computer-assisted (1)
- conical coupling (1)
- conometric connection (1)
- corneas (1)
- cryptic species (1)
- cytarabine dose (1)
- dE/dx (1)
- data quality (1)
- depression (1)
- deswelling (1)
- detector (1)
- diagnostic imaging (1)
- differentiating species (1)
- disease prevalence (1)
- docetaxel (1)
- docetaxel (DX) resistance (1)
- drug resistance (1)
- dual-energy (1)
- easyPACId (1)
- ectosomes (1)
- effective lens position (1)
- elderly (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- eltrombopag (1)
- energy-dispersive x-ray spectroscopy (1)
- epigenomics (1)
- epiregulin (1)
- ethical trade-off (1)
- eutrophication (1)
- excitation (1)
- exosomes (1)
- experimental results (1)
- explainable AI (1)
- extinction (1)
- extracellular vesicles (1)
- fear conditioning (1)
- fibrotest (1)
- fluorine (1)
- foraminifera (1)
- foraminifers (1)
- forest classification (1)
- forest functional similarity (1)
- fragment-based screening (1)
- functional genetics (1)
- gadobutrol (1)
- gene family (1)
- genetic generalized epilepsy (1)
- genome evolution (1)
- geophysical prospections (1)
- germ cell tumors (1)
- glioblastoma (1)
- glioblastoma survival (1)
- global change (1)
- graft rejection (1)
- graft-versus host (1)
- grasshopper communities (1)
- guidelines (1)
- habitat destruction (1)
- head-and-neck cancer (1)
- health information exchange (1)
- healthcare (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- hepatocellular carcinoma (1)
- high-pitch (1)
- highly-charged ions (1)
- histology (1)
- hospital exemption (1)
- human cytomegalovirus (1)
- human knockout model (1)
- hypertension, pulmonary (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immunity (1)
- immunohistochemistry (1)
- infection control (1)
- integrative taxonomy (1)
- interoperability (1)
- interventional radiology (1)
- intraarterial therapy (1)
- intrinsically disordered region (1)
- invasive species (1)
- iron chelation (1)
- ischemic type biliary lesions (1)
- keratoplasty (1)
- kidney formation (1)
- kinase inhibitor (1)
- knockout mouse (1)
- lamotrigine (1)
- learning (1)
- levetiracetam (1)
- liver fibrosis (1)
- liver metastases (1)
- liver metastasis (1)
- liver transplantation (1)
- livermetastases of colorectal cancer (1)
- local radiotherapy (1)
- locoregional chemotherapy (1)
- long non-coding RNA (1)
- low-dose imaging (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- mTOR (1)
- mTOR inhibitor (1)
- macrophage (1)
- magnetic gradiometry (1)
- marginal fit (1)
- medial prefrontal cortex (mPFC) (1)
- memory consolidation and extinction (1)
- mesenchymal stromal cell (1)
- metastasis (1)
- metastatic prostate cancer (1)
- microdosing (1)
- microkeratome (1)
- microlaparoscopy (1)
- micropalaeontology (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- minimally invasive surgery (1)
- molecular characteristics (1)
- mortality (1)
- motility (1)
- multicenter study (1)
- multidetector computed tomography (1)
- multivariate mixed model (1)
- natural products (1)
- necroptosis (1)
- neovascularization, physiologic (1)
- neutralizing antibodies (1)
- nitrogen deposition (1)
- nocardia (1)
- nocardiosis (1)
- non-invasive fibrosis assessment (1)
- non-small cell lung cancer (1)
- nonstructural proteins (1)
- optical coherence tomography (1)
- orthology (1)
- orthopic liver transplantation (1)
- ovary (1)
- p+p collisions (1)
- pediatric (1)
- pediatric patients (1)
- pediatric robotic surgery (1)
- penile cancer (1)
- personality (1)
- pharmacoresistance (1)
- phylogenetic community distance (1)
- phylogenetic signal (1)
- point shear wave elastography (1)
- portal vein (1)
- portosystemic shunt (1)
- predictive biomarkers (1)
- prognostic biomarker (1)
- prostate cancer (1)
- prostate cancer (PCa) (1)
- proteins (1)
- proteobacteria (1)
- proteomics (1)
- pseudoexfoliative syndrome (1)
- pulmonary embolism (1)
- pulmonary nocardiosis (1)
- qualitative research (1)
- quality control (1)
- quantum electrodynamics test (1)
- quark gluon plasma (1)
- radiomics (1)
- rare diseases (1)
- re-exposure (1)
- rechallenge (1)
- recurrence pattern (1)
- refractory aGvHD (1)
- reintroduction (1)
- relativistic collisions (1)
- renal impairment (1)
- repeatability (1)
- reproducibility (1)
- resistance (1)
- resistant cell lines (1)
- retrospective trial (1)
- rigor (1)
- robotically assisted surgery (1)
- robotics (1)
- schizophrenia (1)
- sea-level indicator (1)
- semi-dry grassland (1)
- sequential ALK-inhibitor therapy (1)
- sex (1)
- shikonin (SHI) (1)
- simplified production (1)
- single subject classification (1)
- smart home (1)
- smart living (1)
- soil nutrients (1)
- song evolution (1)
- spectra (1)
- sphingolipids (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- squamous cell carcinoma (1)
- stage II/III colorectal cancer (1)
- standardization (1)
- steroid-resistant aGvHD (1)
- strong Coulomb field (1)
- structural habitat types (1)
- structural proteins (1)
- survival (1)
- targeted therapy (1)
- temporal classification (1)
- testis (1)
- therapeutic anticoagulation (1)
- thrombopietin receptor agonist (1)
- thrombosis (1)
- transcranial magnetic stimulation (TMS) (1)
- transient elastography (1)
- transmission (1)
- transplantation (1)
- treatment resistance (1)
- tropical forests (1)
- trust (1)
- trustworthy AI (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (TKI) (1)
- urinary tract development (1)
- uveal melanoma (1)
- valproic acid (1)
- variants of concern (1)
- vegetation-plot data (1)
- web of things (1)
- whole-genome sequencing (1)
- x-ray techniques (1)
- zebrafish development (1)
- Öffentlichkeit (1)
- ΔNp63 (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1114)
- Frankfurt Institute for Advanced Studies (FIAS) (948)
- Informatik (915)
- Medizin (162)
- Geowissenschaften (39)
- Institut für Ökologie, Evolution und Diversität (14)
- Biowissenschaften (13)
- Biodiversität und Klima Forschungszentrum (BiK-F) (10)
- Senckenbergische Naturforschende Gesellschaft (8)
- ELEMENTS (7)
The first study of ϕ-meson production in p–Pb collisions at forward and backward rapidity, at a nucleon–nucleon centre-of-mass energy √sNN=5.02 TeV, has been performed with the ALICE apparatus at the LHC. The ϕ-mesons have been identified in the dimuon decay channel in the transverse momentum (pT) range 1<pT<7 GeV/c, both in the p-going (2.03<y<3.53) and the Pb-going (−4.46<y<−2.96) directions — where y stands for the rapidity in the nucleon–nucleon centre-of-mass — the integrated luminosity amounting to 5.01±0.19 nb−1 and 5.81±0.20 nb−1, respectively, for the two data samples. Differential cross sections as a function of transverse momentum and rapidity are presented. The forward–backward ratio for ϕ-meson production is measured for 2.96<|y|<3.53, resulting in a ratio ∼0.5 with no significant pT dependence within the uncertainties. The pT dependence of the ϕ nuclear modification factor RpPb exhibits an enhancement up to a factor 1.6 at pT=3–4 GeV/c in the Pb-going direction. The pT dependence of the ϕ-meson cross section in pp collisions at √s=2.76 TeV, which is used to determine a reference for the p–Pb results, is also presented here for 1<pT<5 GeV/c and 2.5<y<4, for a 78±3 nb−1 integrated luminosity sample.
ϕ meson measurements provide insight into strangeness production, which is one of the key observables for the hot medium formed in high-energy heavy-ion collisions. ALICE measured ϕ production through its decay in muon pairs in Pb–Pb collisions at sNN−−−√=2.76 TeV in the intermediate transverse momentum range 2<pT<5 GeV/c and in the rapidity interval 2.5<y<4. The ϕ yield was measured as a function of the transverse momentum and collision centrality. The nuclear modification factor was obtained as a function of the average number of participating nucleons. Results were compared with the ones obtained via the kaon decay channel in the same pT range at midrapidity. The values of the nuclear modification factor in the two rapidity regions are in agreement within uncertainties.
Inclusive ϒ(1S) and ϒ(2S) production have been measured in Pb–Pb collisions at the centre-of-mass energy per nucleon–nucleon pair √sNN = 5.02 TeV, using the ALICE detector at the CERN LHC. The ϒ mesons are reconstructed in the centre-of-mass rapidity interval 2.5 < y < 4 and in the transversemomentum range pT < 15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive ϒ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The ϒ(1S) and ϒ(2S) RAA, integrated over the centrality range 0–90%, are 0.37± 0.02(stat) ± 0.03(syst) and 0.10 ± 0.04(stat) ± 0.02(syst), respectively, leading to a ratio Rϒ(2S) AA /Rϒ(1S) AA of 0.28±0.12(stat)±0.06(syst). The observed ϒ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
Inclusive Υ(1S) and Υ(2S) production have been measured in Pb-Pb collisions at the centre-of-mass energy per nucleon-nucleon pair sNN−−−√=5.02 TeV, using the ALICE detector at the CERN LHC. The Υ mesons are reconstructed in the centre-of-mass rapidity interval 2.5<y<4 and in the transverse-momentum range pT<15 GeV/c, via their decays to muon pairs. In this Letter, we present results on the inclusive Υ(1S) nuclear modification factor RAA as a function of collision centrality, transverse momentum and rapidity. The Υ(1S) and Υ(2S) RAA, integrated over the centrality range 0-90%, are 0.37±0.02(stat)±0.03(syst) and 0.10±0.04(stat)±0.02(syst), respectively, leading to a ratio RΥ(2S)AA/RΥ(1S)AA of 0.28±0.12(stat)±0.06(syst). The observed Υ(1S) suppression increases with the centrality of the collision and no significant variation is observed as a function of transverse momentum and rapidity.
ϒ production in p–Pb interactions is studied at the centre-of-mass energy per nucleon–nucleon collision √sNN = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03 < ycms < 3.53 and −4.46 < ycms < −2.96, down to zero transverse momentum. In this work, results on the ϒ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the ϒ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the ϒ(2S) nuclear modification factor is evaluated, suggesting a suppression similar to that of the ϒ(1S). A first measurement of the ϒ(3S) has also been performed. Finally, results are compared with previous ALICE measurements in p–Pb collisions at √sNN = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
Υ production in p-Pb interactions is studied at the centre-of-mass energy per nucleon-nucleon collision sNN−−−√ = 8.16 TeV with the ALICE detector at the CERN LHC. The measurement is performed reconstructing bottomonium resonances via their dimuon decay channel, in the centre-of-mass rapidity intervals 2.03<ycms<3.53 and −4.46<ycms<−2.96, down to zero transverse momentum. In this work, results on the inclusive Υ(1S) production cross section as a function of rapidity and transverse momentum are presented. The corresponding nuclear modification factor shows a suppression of the Υ(1S) yields with respect to pp collisions, both at forward and backward rapidity. This suppression is stronger in the low transverse momentum region and shows no significant dependence on the centrality of the interactions. Furthermore, the Υ(2S) nuclear modification factor is also evaluated, suggesting a suppression similar to that of the Υ(1S). A first measurement of the Υ(3S) has also been performed. Finally, results are compared with previous measurements performed by ALICE in p-Pb collisions at sNN−−−√ = 5.02 TeV and with theoretical calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02TeV
(2021)
The production of ϒ mesons in Pb–Pb collisions at a centre-of-mass energy per nucleon pair √sNN = 5.02 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5 < y < 4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the ϒ(1S) meson is suppressed by a factor of about three with respect to the production in proton–proton collisions. For the first time, a significant signal for the ϒ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2–3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.
ϒ production and nuclear modification at forward rapidity in Pb–Pb collisions at √sNN = 5.02 TeV
(2021)
The production of Υ mesons in Pb-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√ = 5 TeV is measured with the muon spectrometer of the ALICE detector at the LHC. The yields as well as the nuclear modification factors are determined in the forward rapidity region 2.5<y<4.0, as a function of rapidity, transverse momentum and collision centrality. The results show that the production of the Υ(1S) meson is suppressed by a factor of about three with respect to the production in proton-proton collisions. For the first time, a significant signal for the Υ(2S) meson is observed at forward rapidity, indicating a suppression stronger by about a factor 2-3 with respect to the ground state. The measurements are compared with transport, hydrodynamic, comover and statistical hadronisation model calculations.